Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance.
Acromegaly is associated with insulin resistance and an increased incidence of cardiovascular disease. However, it remains unclear to what extent the effects of growth hormone (GH) excess on cardiovascular morbidity and mortality are mediated through insulin resistance versus through other direct or indirect effects of GH. Adequate control of GH excess by surgery or pharmacologic interventions is associated with decreased insulin resistance, reflected in decreased plasma insulin levels and fasting glucose levels or improved glucose tolerance. Despite divergent effects of both somatostatin and somatostatin analogs on GH, insulin and glucagon secretion, and glucose absorption, treatment with the somatostatin analogs octreotide and lanreotide has only limited effects on glucose metabolism. However, glucose sensitivity has only been formally examined using a hyperinsulinemic euglycemic clamp in a minority of these studies. Treatment with the GH-receptor antagonist pegvisomant ameliorates insulin sensitivity, reflected in decreased fasting plasma insulin levels and fasting glucose levels. Nonetheless, the effect of pegvisomant on glucose sensitivity has not been formally tested by hyperinsulinemic clamp conditions. In acromegaly, preliminary observations on new octreotide analogs with greater specificity for somatostatin-receptor subtypes indicate that these compounds achieve better control of GH hypersecretion than octreotide, but may also negatively influence insulin release. Assessment of insulin secretion and glucose levels in acromegalic patients during administration of these compounds is thus mandatory.
Pereira
Alberto M
AM
Department of Endocrinology & Metabolism, Leiden University Medical Center, Leiden, The Netherlands. A.M.Pereira@lumc.nl
Biermasz
Nienke R
NR
Roelfsema
Ferdinand
F
Romijn
Johannes A
JA
D000172:Acromegaly / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D018149:Glucose Intolerance; D013006:Growth Hormone / Q000502:physiology; D006801:Humans; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D000078790:Insulin Secretion; D007334:Insulin-Like Growth Factor I / Q000502:physiology; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000009:adverse effects / Q000627:therapeutic use; D017481:Receptors, Somatostatin / Q000627:therapeutic use; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors; D013004:Somatostatin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
C423390:BIM-23244; D001786:Blood Glucose; D007328:Insulin; D010456:Peptides, Cyclic; D017481:Receptors, Somatostatin; D011986:Receptors, Somatotropin; C060347:lanreotide; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; C517782:pasireotide; D015282:Octreotide